Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eicosapentaenoic acid + docosahexaenoic acid (Atrium Innovations Inc.)
- Development stage
- Phase 2
- Lead developer
- Douglas Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Opti-EPA is a concentrated dietary supplement containing the omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), typically derived from marine fish oil. It is utilized as a nutritional intervention to modulate lipid metabolism and inflammatory pathways. In clinical research, specifically a Phase 2 trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Opti-EPA has been evaluated for its potential to improve liver histology and reduce microscopic changes in patients with non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus. The mechanism of action involves serving as a ligand for peroxisome proliferator-activated receptors (PPARs), which regulate lipid metabolism and glucose homeostasis, and serving as a precursor to specialized pro-resolving mediators (SPMs) that dampen inflammation.
- Brand names
- Opti-EPA
- Other names
- omega-3 fatty acidsomega3 fatty acidsomega 3 fatty acidsfish oilEPA/DHA
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on eicosapentaenoic acid + docosahexaenoic acid (Atrium Innovations Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eicosapentaenoic acid + docosahexaenoic acid (Atrium Innovations Inc.).